TABLE 2.

Novel Neuroprotective Agents under Development, July 2003

Agent	Type of Agent	Type of Studies	Comments
BAY 38-7271	Cannabinoid agonist	Phase I	Demonstrated highly potent and efficient neuroprotective properties when administered immediately after induction of subdural hematoma (70% infarct volume reduction); even when applied with a 3-h delay, a significant neuroprotective efficacy could be observed (59% infarct volume reduction)77
NS 1209	AMPA antagonist	Phase I	No data available
S-1746	AMPA antagonist	Phase I	No data available
ARR-15896AR	NMDA antagonist	Preclinical	No data available
BAY 44-2041	Adenosine re-uptake inhibitor	Preclinical	Increases perfusion in TBI; no data available
Immunophilins	Immunosupressants	Prerclinical	Neuroprotectant properties in TBI78
NAALADase inhibitors	NAALADase inhibitors	Preclinical	Neuroprotectant properties in ischemia, TBI79